Antiinflammatory effects of aspirin in ACS: Relevant to its cardio coronary actions?

Thrombosis and Haemostasis

Volumn 114, Issue 3, 2015, Pages 469-477

  Hohlfeld, Thomas ^a   Schrör, Karsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aspirin; Inflammatory mediators; Platelet pharmacology; Thrombin; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CD40 ANTIGEN; CYCLOOXYGENASE 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; SPHINGOSINE 1 PHOSPHATE; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; AUTACOID; BIOLOGICAL MARKER; THROMBIN;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; HEART INFARCTION; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULITIS; ANIMAL; BLOOD; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION; THROMBOCYTE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; BLOOD PLATELETS; HUMANS; INFLAMMATION MEDIATORS; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION; THROMBIN; TREATMENT OUTCOME;

EID: 84940649136     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-03-0191     Document Type: Article

References (104)

1. Hohlfeld T, Schrör K. Aspirin. In: Antiplatelet Therapy. Wiley 2014; pp. 111-116
2. Morris T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 2009; 183: 2089-2096
3. Ikonomidis I, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-798
4. Kennon S, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001; 37: 1266-1270
5. Ridker PM, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979
6. Ridker PM, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733
7. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010; 103: 71-82
8. Ulrych T, et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011; 9: 790-798
9. Polzin A, et al. Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction. Int J Cardiol 2013; 170: e23-24
10. Passacquale G, Ferro A. Current concepts of platelet activation: Possibilities for therapeutic modulation of heterotypic vs. Homotypic aggregation. Br J Clin Pharmacol 2011; 72: 604-618
11. Weyrich AS, et al. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897-1905
12. Libby P, et al. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014; 114: 1867-1879
13. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695
14. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488
15. Langer HF, et al. Interaction of platelets and inflammatory endothelium in the development and progression of coronary artery disease. Semin Thromb Hemost 2010; 36: 131-138
16. Zimmerman GA, Weyrich AS. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008; 28: s17-24
17. Gawaz M, et al. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384
18. Brummel KE, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-152
19. Alexander KS, et al. Role of electrostatic interactions in binding of thrombin to the fibrinogen gamma’ chain. Biochemistry 2012; 51: 3445-3450
20. Kalz J, et al. Thrombin generation and atherosclerosis. J Thromb Thrombolysis 2014; 37: 45-55
21. Popovic M, et al. Thrombin and vascular inflammation. Mol Cell Biochem 2012; 359: 301-313
22. Domsalla A, Melzig MF. Enhancement of protease-induced IL-6 release in monocytic U-937 cells by phorbol-12-myristate-13-acetate. Inflamm Res 2012; 61: 1125-1129
23. Gawaz M, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75-85
24. Yasu T, et al. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. Am J Cardiol 1993; 71: 1164-1168
25. Merlini PA, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68
26. Ardissino D, et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 2003; 102: 2731-2735
27. Capra V, et al. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost 2014; 12: 126-137
28. Gabrielsen A, et al. Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. J Mol Med 2010; 88: 795-806
29. Cherdon C, et al. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins Other Lipid Mediat 2011; 94: 124-132
30. Petri MH, et al. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. Biochem Biophys Res Commun 2013; 441: 393-398
31. Eikelboom JW, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712
32. Matsuura E, et al. On aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes. J Thromb Haemost 2012; 10: 1949-1951
33. Rauch BH. Sphingosine 1-phosphate as a link between blood coagulation and inflammation. Cell Physiol Biochem 2014; 34: 185-196
34. Takeya H, et al. Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood 2003; 102: 1693-1700
35. Ulrych T, et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011; 9: 790-798
36. Gude DR, et al. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a „come-and-get-me“ signal. FASEB J 2008; 22: 2629-2638
37. Mahajan-Thakur S, et al. Sphingosine-1-phosphate induces thrombin receptor PAR-4 expression to enhance cell migration and COX-2 formation in human monocytes. J Leukoc Biol 2014; 96: 611-618
38. Santilli F, et al. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. J Am Heart Assoc 2014; 3: 1-13
39. Valgimigli M, et al. Prasugrel versus tirofiban bolus with or without short postbolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012; 5: 268-277
40. Montalescot G, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027
41. Szczeklik A, et al. Antiplatelet Drugs and Generation of Thrombin in Clotting Blood. Blood 1992; 80: 2006-2011
42. Kessels H, et al. Measurement of thrombin generation in whole blood--the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83
43. Undas A, et al. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007; 109: 2285-2292
44. Wallen NH, Ladjevardi M. Influence of low-and high-dose aspirin treatment on thrombin generation in whole blood. Thromb Res 1998; 92: 189-194
45. Wolzt M, et al. Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thromb Res 2013; 132: 240-247
46. Undas A, et al. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. Thromb Haemost 2007; 97: 1056-1058
47. Schrör K, et al. Functional testing methods for the antiplatelet effects of aspirin. Biomark Med 2011; 5: 31-42
48. Berk BC, et al. Elevation of C-reactive protein in „active“ coronary artery disease. Am J Cardiol 1990; 65: 168-172
49. de Beer FC, et al. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982; 47: 239-243
50. Pietila K, et al. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J 1993; 14: 915-919
51. Liuzzo G, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-424
52. Soejima H, et al. Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial. J Cardiol 2013; 62: 165-170
53. Ridker PM. Inflammation, C-reactive protein, and cardiovascular disease: moving past the marker versus mediator debate. Circ Res 2014; 114: 594-595
54. Grinstein J, Cannon CP. Aspirin resistance: Current status and role of tailored therapy. Clin Cardiol 2012; 35: 673-681
55. Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther 2014; 141: 69-78
56. Feng D, et al. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 2000; 9: 37-41
57. Feldman M, et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001; 37: 2036-2041
58. Azar RR, et al. Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am J Cardiol 2003; 92: 236-239
59. Hovens MM, et al. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabetes Obes Metab 2008; 10: 668-674
60. Kim MA, et al. The effect of aspirin on C-reactive protein in hypertensive patients. Clin Exp Hypertens 2011; 33: 47-52
61. Rogowski O, et al. Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events. Blood Coagul Fibrinolysis 2006; 17: 19-22
62. Fisher M, et al. An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. Am Heart J 2008; 156: 106-111
63. Vaucher J, et al. Cytokines and hs-CRP levels in individuals treated with lowdose aspirin for cardiovascular prevention: a population-based study (CoLaus Study). Cytokine 2014; 66: 95-100
64. Solheim S, et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006; 96: 660-664
65. Ikonomidis I, et al. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J 2005; 149: 832-839
66. Gao XR, et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. J Pharm Pharmacol 2009; 61: 1505-1510
67. Kronish IM, et al. Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. Am J Cardiol 2010; 106: 1090-1094
68. Solheim S, et al. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 2003; 92: 843-845
69. Tousoulis D, et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 2014; 63: 2491-2502
70. Owens CD. Statins and other agents for vascular inflammation. J Vasc Surg 2012; 56: 1799-1806
71. Souza JR, et al. Serum levels of interleukin-6 (IL-6), interleukin-18 (IL-18) and C-reactive protein (CRP) in patients with type-2 diabetes and acute coronary syndrome without ST-segment elevation. Arq Bras Cardiol 2008; 90: 86-90
72. Maier W, et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005; 111: 1355-1361
73. Oemrawsingh RM, et al. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart 2011; 97: 1061-1066
74. Kaptoge S, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 2014; 35: 578-589
75. Novo G, et al. Clinical significance of macrophage colony stimulating factor levels in acute coronary syndrome. Minerva Cardioangiol 2009; 57: 7-11
76. Chen YG, et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32-36
77. Muller K, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010; 213: 256-262
78. Gori AM, et al. The balance between pro-and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009; 202: 255-262
79. Chiang N, et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006; 58: 463-487
80. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010; 107: 1170-1184
81. Brancaleone V, et al. A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 2013; 122: 608-617
82. Chiang N, et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 2004; 101: 15178-15183
83. Fitz Gerald GA, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688
84. McAdam BF, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-277
85. Napoli C, et al. Nitric oxide and atherosclerosis: an update. Nitric Oxide 2006; 15: 265-279
86. Taubert D, et al. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 2004; 143: 159-165
87. O’Kane PD, et al. Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment. Cardiovasc Res 2003; 59: 152-159
88. Grosser N, et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun 2003; 308: 956-960
89. Hetzel S, et al. Aspirin increases nitric oxide formation in chronic stable coronary disease. J Cardiovasc Pharmacol Ther 2013; 18: 217-221
90. Hennekens CH, et al. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. J Cardiovasc Pharmacol Ther 2010; 15: 344-348
91. Magen E, et al. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertension 2005; 19: 667-673
92. Czibik G, et al. Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology. Basic Res Cardiol 2014; 109: 450
93. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-959
94. Dragomir E, et al. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vasc Pharmacol 2006; 44: 440-449
95. Weber C, et al. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995; 91: 1914-1917
96. Nagelschmitz J, et al. Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol 2014; 6: 51-59
97. Yin MJ, et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77-80
98. Liu H, et al. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 2010; 24: 17-24
99. Cyrus T, et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002; 106: 1282-1287
100. Saunders MA, et al. Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. J Biol Chem 2001; 276: 18897-18904
101. Mehta JL, et al. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 2004; 64: 243-249
102. Yuan MS, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of IKK beta. Science 2001; 293: 1673-1677
103. Wu R, et al. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 2002; 105: 387-392
104. Dikshit P, et al. Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem 2006; 281: 29228-29235.